Literature DB >> 11705857

Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers.

J R Whetstine1, A J Gifford, T Witt, X Y Liu, R M Flatley, M Norris, M Haber, J W Taub, Y Ravindranath, L H Matherly.   

Abstract

The presence of sequence variants in the human reduced folate carrier (hRFC) was assessed in leukemia blasts from children with acute lymphoblastic leukemia (ALL) and in normal peripheral blood specimens. A CATG frame shift insertion at position 191 was detected in 10-60% of hRFC transcripts from 10 of 16 ALL specimens, by RFLP analysis and direct sequencing of hRFC cDNAs. In genomic DNAs prepared from 105 leukemia (n = 54) and non-leukemia (n = 51) specimens, PCR amplifications and direct sequencing of exon 3 identified a high-frequency G to A single nucleotide polymorphism at position 80 that resulted in a change of arginine-27 to histidine-27. The allelic frequencies of G/A80 were nearly identical for the non-leukemia (42.2% CGC and 57.8% CAC) and leukemia (40.7% CGC and 59.3% CAC) genomic DNAs. In cDNAs prepared from 10 of these ALL patients, identical allelic frequencies (40 and 60%, respectively) were recorded. In up to 62 genomic DNAs, hRFC-coding exons 4-7 were PCR-amplified and sequenced. A high-abundance C/T696 polymorphism was detected with nearly identical frequencies for both alleles, and a heterozygous C/A1242 sequence variant was identified in two ALL specimens. Both C/T696 and C/A1242 were phenotypically silent. In transport assays with [(3)H]methotrexate and [(3)H]5-formyl tetrahydrofolate, nearly identical uptake rates were measured for the arginine-27- and histidine-27-hRFC proteins expressed in transport-impaired K562 cells. Although there were no significant differences between the kinetic parameters for methotrexate transport for the hRFC forms, minor (approximately 2-fold) differences were measured in the K(i)s for other substrates including Tomudex, 5,10-dideazatetrahydrofolate, GW1843U89, and 10-ethyl-10-deazaaminopterin and for 5-formyl tetrahydrofolate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705857

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number.

Authors:  Jannie Gregers; Ib Jarle Christensen; Kim Dalhoff; Birgitte Lausen; Henrik Schroeder; Steen Rosthoej; Niels Carlsen; Kjeld Schmiegelow; Curt Peterson
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

3.  SLC19A1 pharmacogenomics summary.

Authors:  Sook Wah Yee; Li Gong; Ilaria Badagnani; Kathleen M Giacomini; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-11       Impact factor: 2.089

Review 4.  The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.

Authors:  Larry H Matherly; Mike R Wilson; Zhanjun Hou
Journal:  Drug Metab Dispos       Date:  2014-01-06       Impact factor: 3.922

5.  Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy.

Authors:  Anthoula Chatzikyriakidou; Ioannis Georgiou; Paraskevi V Voulgari; Christos G Papadopoulos; Theodoros Tzavaras; Alexandros A Drosos
Journal:  Rheumatol Int       Date:  2007-04-03       Impact factor: 2.631

6.  Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

Authors:  Araba A Adjei; Oreste E Salavaggione; Sumithra J Mandrekar; Grace K Dy; Katie L Allen Ziegler; Chiaki Endo; Julian R Molina; Steven E Schild; Alex A Adjei
Journal:  J Thorac Oncol       Date:  2010-09       Impact factor: 15.609

7.  Ancestry and pharmacogenetics of antileukemic drug toxicity.

Authors:  Shinji Kishi; Cheng Cheng; Deborah French; Deqing Pei; Soma Das; Edwin H Cook; Nobuko Hijiya; Carmelo Rizzari; Gary L Rosner; Tony Frudakis; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Blood       Date:  2007-01-30       Impact factor: 22.113

Review 8.  Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.

Authors:  Rongbao Zhao; Larry H Matherly; I David Goldman
Journal:  Expert Rev Mol Med       Date:  2009-01-28       Impact factor: 5.600

9.  Reduced folate carrier-1 G80a gene polymorphism is associated with neuroblastoma's development.

Authors:  Dyego O de Miranda; Jemima E X S Barros; Maria Madalena S Vieira; Elker L S Lima; Vera L L Moraes; Helker A da Silva; Helder L B O Garcia; Cássia A Lima; Adriana V Gomes; Neide Santos; Maria T C Muniz
Journal:  Mol Biol Rep       Date:  2014-04-27       Impact factor: 2.316

10.  The association of idiopathic recurrent early pregnancy loss with polymorphisms in folic acid metabolism-related genes.

Authors:  Yunlei Cao; Zhaofeng Zhang; Yanmin Zheng; Wei Yuan; Jian Wang; Hong Liang; Jianping Chen; Jing Du; Yueping Shen
Journal:  Genes Nutr       Date:  2014-04-12       Impact factor: 5.523

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.